• Center on Health Equity and Access
  • Clinical
  • Health Care Cost
  • Health Care Delivery
  • Insurance
  • Policy
  • Technology
  • Value-Based Care

Strides Said to Consider Sale of Injectable-Drugs Unit

Article

Strides Arcolab Ltd. (STR)

, a supplier of cancer-fighting drugs to Pfizer Inc., is considering selling its injectable-medicines unit, three people with knowledge of the matter said.

market value

The unit, called Agila Specialties, may be valued at more than Bangalore-based Strides’s current of about $800 million, two people said, declining to be identified as the information is private. Agila’s relative success in winning approvals for new products and the scarcity of facilities able to manufacture injectable medicines make it an attractive target for drugmakers, they said.

Read the full story: http://tinyurl.com/9c5zogt

Source: Bloomberg

Related Videos
Video 15 - "Ensuring Fair Cardiovascular Care for All: Concluding Perspectives on Disparities and Inclusion"
Shawn Tuma, JD, CIPP/US, cybersecurity and data privacy attorney, Spencer Fane LLP
Ryan Stice, PharmD
Raajit Rampal, MD, PhD, screenshot
Leslie Fish, PharmD.
Ronesh Sinha, MD
Adam Colborn, JD
Beau Raymond, MD
Judith Alberto, MHA, RPh, BCOP, director of clinical initiatives, Community Oncology Alliance
Related Content
© 2024 MJH Life Sciences
AJMC®
All rights reserved.